Arbutus Biopharma
ABUS
55 hedge funds and large institutions have $88.8M invested in Arbutus Biopharma in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
65.99% more ownership
Funds ownership: 0% → 65.99% (+66%)
15% more funds holding
Funds holding: 48 → 55 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less capital invested
Capital invested by funds: $115M → $88.8M (-$26.2M)
48% less call options, than puts
Call options by funds: $620K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$15.4M |
| 2 |
AC
Armistice Capital
New York
|
+$1.57M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$978K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$681K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$466K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$6.88M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$2.8M |
| 3 |
Millennium Management
New York
|
-$1.33M |
| 4 |
SCM
Suffolk Capital Management
New York
|
-$1.08M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$809K |
ABUS Hedge Fund Activity: Q4 2016 in Review
55 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2016, worth a combined $88.8M — down 23% from $115M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ABUS positions and 7 closed out — a net gain of 7 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $15.4M. The largest seller was HealthCor Management, exiting entirely with an estimated $6.88M sold.
- 55 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2016, up from 48 in Q3 2016.
- Funds reported $88.8M of Arbutus Biopharma stock for Q4 2016, down 23% quarter-over-quarter.
- 14 funds opened new Arbutus Biopharma positions in Q4 2016 and 7 closed out, a net change of +7 holders.
- The largest Arbutus Biopharma buyer in Q4 2016 was Ladenburg Thalmann Financial Services, an estimated $15.4M added.
- The largest Arbutus Biopharma seller in Q4 2016 was HealthCor Management, an estimated $6.88M sold.
Based on aggregated 13F filings for Q4 2016.